I keep hearing the same explanation for decades of lost psychedelic research: Timothy Leary frightened the public and ruined everything. The lesson for the rest of us is to behave.

We should stop repeating this story. It shifts responsibility from the people who imposed and maintained prohibition to a man who challenged them. It also reduces the losses to missed research. Religious freedom, self-exploration and human flourishing belong in this history too.

In 2018, Michael Pollan acknowledged that the moral panic around LSD probably would have happened without Leary. He then said: “But on the research side, it really was Leary who provoked the psychiatric establishment to turn against LSD.”^[1] I think that gives Leary’s mistakes too much weight.

Carl Hart made a broader claim in a 2013 interview: “His antics set back the research into hallucinogens 40 years.” Hart was discussing research safeguards. He has also challenged drug prohibition. Even its critics repeat the story.^[2]

Leary deserves a fairer hearing. Before he became a countercultural celebrity, he studied personality and human relationships. At Harvard, he and Richard Alpert investigated how psilocybin changed consciousness and recorded volunteers’ accounts. Taking those experiences seriously was a worthwhile scientific undertaking.^[3]

His Concord Prison Experiment asked whether psychedelic sessions could help prisoners avoid returning to prison. Later scrutiny undermined its claims about reduced reoffending. Its ambition still matters: he sought ways to help people change their lives.^[4]

He also brought questions about consciousness and personal freedom into public discussion. Who should be allowed to explore these experiences? Who should decide their meaning? These questions remain with us. His interest in them deserves attention alongside his mistakes.

Harvard colleagues raised serious concerns about participant safety, weak research controls and investigators taking psilocybin during studies.^[3] Those practices deserve criticism. His influence on the backlash deserves scrutiny. Neither establishes that he cost science forty years.

Leary did not control Congress, regulatory agencies, university budgets or pharmaceutical companies. Explaining their decisions requires examining their records. A judgment about his character cannot substitute for that work.

The crackdown on psychedelics extended a much older system of prohibition. San Francisco’s 1875 opium-den ordinance targeted a practice associated with Chinese immigrants. Racist claims about cocaine and Black people helped build support for drug control. Anti-Mexican prejudice appeared in the campaign against marijuana.^[5]

In the 1937 marijuana tax hearings, Harry Anslinger submitted a letter seeking federal action against a supposed menace among “degenerate Spanish-speaking residents.” The prejudice was part of the case presented to Congress.^[6]

LSD later became associated with youth rebellion and opposition to the Vietnam War.^[7] Officials confronted that movement with laws and agencies already accustomed to treating drug users as threats to public order. Leary did not build that system.

Research declined through several decisions and pressures. The 1962 drug amendments strengthened requirements for proving effectiveness. Psychedelic psychotherapy fit awkwardly into trials designed to isolate a drug’s effects: participants could often identify what they had taken, and the therapy depended on relationships and setting.^[8]

Historian Matthew Oram found that federal agencies helped sustain LSD studies after Sandoz withdrew its sponsorship in 1966. Some continued into the mid-1970s. He gives greater weight to difficulties in testing the treatment and declining psychiatric interest than to criminal prohibition in explaining the early collapse.^[8]

That history must also account for the burden of conducting research under drug prohibition. The 1970 Controlled Substances Act placed LSD in Schedule I.^[9] Research remained legally possible, but the system imposed controlled-drug permissions and handling requirements on top of ordinary research oversight.

Researchers have documented the consequences. A guide published in 2024 describes separate federal registration, state licenses where required, inspections, secure storage, drug-accountability records and further submissions for additional substances. Some state requirements for suppliers could add months.^[10] In 2013, laboratory researchers had already described licensing delays and repeated paperwork as obstacles to their work.^[11]

Those requirements consume staff time and money before a study produces a finding. Legal permission means little to a researcher who cannot afford the process. Calling the work “not banned” leaves out how difficult and expensive the rules made it.

We lost opportunities to test claims, identify harms and build knowledge. No one can calculate the treatments that uninterrupted research might have produced.

Drug-war propaganda has shaped public understanding, including within the psychedelic field. Those of us who write, teach and speak about psychedelics should examine the stories we pass on.

The Leary story teaches a political lesson too: stay respectable, avoid controversy, and perhaps authorities will leave you alone. It encourages the field to distance itself from religious practice, counterculture and uses that medicine cannot explain. I think that asks us to surrender too much.

People should not need a diagnosis to justify exploring consciousness. Religious use, creativity and philosophical inquiry are central human concerns. Medicine can help people suffer less without becoming the sole judge of which experiences matter.

Human flourishing includes learning how to live, finding meaning and building relationships. Communities can help people make sense of powerful experiences and examine what follows. Freedom to explore should not depend on proving that an experience produced a better patient, parent or citizen.

The same principle challenges psychedelic exceptionalism. Winning acceptance for psilocybin while leaving other drug users subject to punishment preserves the drug war’s central injustice. Different substances carry different risks. Those differences should guide care and regulation, not determine whose dignity counts.

Consent, honest information and accountability for harm belong in every setting. They do not require us to treat people who use drugs as criminals.

The drug war cost people their freedom, separated families and restricted religious and cultural practices. Its losses cannot be measured only in delayed medicines. A psychedelic field concerned with human flourishing must reckon with the punishment of people whose choices it does not admire.

The officials who enacted and maintained prohibition made choices. We should hold them responsible for those choices and stop blaming Leary.

Sources and editorial notes

1. Tim Adams, “Michael Pollan: ‘I was a very reluctant psychonaut’”, The Guardian, May 12, 2018, archived on Pollan’s website. Retains Pollan’s distinction between the wider moral panic and the psychiatric backlash.
2. “The Scientific Case for Decriminalization”, Reason, October 10, 2013. Hart’s statement appears in his answer about approval and safeguards for research.
3. Harvard Department of Psychology, “Timothy Leary”. Supports the account of his earlier psychological work, the Harvard Psilocybin Project and contemporary criticism of its methods.
4. Rick Doblin, “Dr. Leary’s Concord Prison Experiment: A 34-Year Follow-up Study,” Journal of Psychoactive Drugs 30, no. 4 (1998): 419–426. DOI: 10.1080/02791072.1998.10399715. This primary follow-up examined criminal justice records and interviewed participants and researchers. It found that published treatment-effect claims were erroneous, while identifying further research combining psychedelic psychotherapy with post-release support as a question worth testing.
5. Jennifer D. Oliva and Taleed El-Sabawi, “The ‘New’ Drug War,” Virginia Law Review 110 (2024): 1103–1168, especially 1112–1113, documents the 1875 San Francisco ordinance and racist arguments used to support cocaine criminalization. See also Diana L. Ahmad, “Opium Smoking, Anti-Chinese Attitudes, and the American Medical Community, 1850–1890,” American Nineteenth Century History 1, no. 2 (2000): 53–68. For the limits of explaining marijuana prohibition chiefly through anti-Mexican prejudice, see Isaac Campos, “Mexicans and the Origins of Marijuana Prohibition in the United States: A Reassessment,” The Social History of Alcohol and Drugs 32 (2018): 6–37. The next note supplies direct evidence of racial prejudice in the marijuana campaign; its presence is not presented as a complete explanation for prohibition.
6. Additional statement submitted by Harry J. Anslinger during the 1937 Marihuana Tax Act hearings. The quoted language belongs to Floyd K. Baskette’s September 4, 1936 letter from the Alamosa Daily Courier, which Anslinger submitted; it is not attributed to Anslinger as his own wording.
7. Michaela Barber, John Gardner and Adrian Carter, “History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers”, published online October 4, 2024. Used for political associations, stigma and researchers’ concern about repeating a backlash. Its compressed “ban” narrative is not adopted.
8. Matthew Oram, “Trials of Psychedelic Therapy”, Johns Hopkins University Press, October 4, 2018. The historian summarizes his archival findings, including continued federal support and the difficulties of fitting psychedelic psychotherapy into controlled trials. His interpretation of the early decline is retained rather than presented as evidence that drug-control paperwork alone caused it.
9. 21 U.S.C. § 812, initial statutory schedules. LSD appears in the initial Schedule I. This source establishes the original statutory classification, not the details of all subsequent research requirements.
10. Brian S. Barnett and colleagues, “Practical considerations in the establishment of psychedelic research programs”, published online December 4, 2024; Psychopharmacology 242 (2025): 27–43. Firsthand experience and regulatory guidance on U.S. research programs, including registration, inspections, storage, records, additional substances and state supplier requirements that can add months. The discussion of staff time and financial burden is an inference from these documented tasks, not a claim about a measured cost increase. These later requirements are not projected unchanged back onto the 1960s.
11. Adam Michael Stewart and Allan V. Kalueff, “Controlled substances and innovation of biomedicine: a preclinical perspective”, Nature Reviews Neuroscience 14 (2013): 877. Researchers describe licensing and paperwork barriers in U.S. basic research. Their specific four-week example concerned a cannabis preparation, so it is not presented as an LSD study.

Philosophical background: Kyle Buller, Joe Moore and Lenny Gibson, “A Cultural History of Psychedelics in the US,” in Philosophy and Psychedelics: Frameworks for Exceptional Experience (2022), supplied by Joe in the edited chapter. The broader argument about human flourishing is developed here as Joe’s position.

Scope: U.S. history. This revision distinguishes the early decline in LSD research from later regulatory burdens. It does not claim a blanket research ban, a quantified forty-year loss caused by one person, or a uniform cost or approval timeline. The later research revival and Peaking are omitted as discussed.